NO20015278L - 6-alkenyl-, 6-alkynyl- og 6-epoksy-epotilonderivater, fremgangsmåte for deres fremstilling og deres anvendelse ifarmasöytiske preparater - Google Patents

6-alkenyl-, 6-alkynyl- og 6-epoksy-epotilonderivater, fremgangsmåte for deres fremstilling og deres anvendelse ifarmasöytiske preparater

Info

Publication number
NO20015278L
NO20015278L NO20015278A NO20015278A NO20015278L NO 20015278 L NO20015278 L NO 20015278L NO 20015278 A NO20015278 A NO 20015278A NO 20015278 A NO20015278 A NO 20015278A NO 20015278 L NO20015278 L NO 20015278L
Authority
NO
Norway
Prior art keywords
alkynyl
alkenyl
epoxy
preparation
pharmaceutical preparations
Prior art date
Application number
NO20015278A
Other languages
English (en)
Other versions
NO328149B1 (no
NO20015278D0 (no
Inventor
Ulrich Klar
Wolfgang Schwede
Werner Skuballa
Bernd Buchmann
Jens Hoffmann
Rosemarie Lichtner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19921086A external-priority patent/DE19921086A1/de
Priority claimed from DE19954228A external-priority patent/DE19954228A1/de
Priority claimed from DE10015836A external-priority patent/DE10015836A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20015278D0 publication Critical patent/NO20015278D0/no
Publication of NO20015278L publication Critical patent/NO20015278L/no
Publication of NO328149B1 publication Critical patent/NO328149B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20015278A 1999-04-30 2001-10-29 Epoksy-epotilonforbindelser, fremgangsmate for deres fremstilling, deres anvendelse for fremstilling av farmasoytiske preparater og de farmasoytiske preparater. NO328149B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19921086A DE19921086A1 (de) 1999-04-30 1999-04-30 6-Alkenyl- und 6-Alkinyl-Epothilon Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
DE19954228A DE19954228A1 (de) 1999-11-04 1999-11-04 6-Alkenyl-und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
DE10015836A DE10015836A1 (de) 2000-03-27 2000-03-27 6-Alkenyl- und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
PCT/IB2000/000657 WO2000066589A1 (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations

Publications (3)

Publication Number Publication Date
NO20015278D0 NO20015278D0 (no) 2001-10-29
NO20015278L true NO20015278L (no) 2001-12-21
NO328149B1 NO328149B1 (no) 2009-12-21

Family

ID=27213767

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015278A NO328149B1 (no) 1999-04-30 2001-10-29 Epoksy-epotilonforbindelser, fremgangsmate for deres fremstilling, deres anvendelse for fremstilling av farmasoytiske preparater og de farmasoytiske preparater.

Country Status (33)

Country Link
EP (1) EP1173441B1 (no)
JP (2) JP4024003B2 (no)
KR (1) KR100721488B1 (no)
CN (1) CN100368415C (no)
AR (1) AR023792A1 (no)
AT (1) ATE440847T1 (no)
BG (1) BG65601B1 (no)
BR (1) BR0010190A (no)
CA (2) CA2371226C (no)
CY (1) CY1109768T1 (no)
CZ (1) CZ299653B6 (no)
DE (1) DE60042821D1 (no)
DK (1) DK1173441T3 (no)
EA (1) EA011502B1 (no)
EE (1) EE05292B1 (no)
ES (1) ES2331506T3 (no)
HK (1) HK1046681B (no)
HR (1) HRP20010892A2 (no)
HU (1) HUP0201010A3 (no)
IL (1) IL145938A0 (no)
ME (1) MEP13908A (no)
MX (1) MXPA01011039A (no)
NO (1) NO328149B1 (no)
NZ (1) NZ514989A (no)
PE (1) PE20010116A1 (no)
PL (1) PL210762B1 (no)
PT (1) PT1173441E (no)
RS (1) RS51023B (no)
SI (1) SI1173441T1 (no)
SK (1) SK286858B6 (no)
TW (2) TWI280962B (no)
WO (1) WO2000066589A1 (no)
ZA (1) ZA200109859B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2218328T5 (es) 1995-11-17 2011-11-11 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Derivados de epotilón, su preparación y utilización.
HU229833B1 (en) 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
DE10020899A1 (de) * 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
HUP0302567A2 (hu) 2001-01-25 2003-12-29 Bristol-Myers Squibb Co. Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
SK288098B6 (sk) 2001-01-25 2013-07-02 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
BR0207316A (pt) 2001-02-20 2004-02-10 Bristol Myers Squibb Co Derivados de epotilona para o tratamento de tumores refratários
KR20040025895A (ko) 2001-02-20 2004-03-26 브리스톨-마이어스스퀴브컴파니 에포틸론 유도체를 사용하는 치료불응성 종양의 치료
EE05417B1 (et) 2001-03-14 2011-06-15 Bristol-Myers Squibb Company Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias
MXPA03010909A (es) 2001-06-01 2004-02-17 Bristol Myers Squibb Co Derivados de epotilona.
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
WO2003078411A1 (en) 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
TWI291464B (en) 2002-09-23 2007-12-21 Bristol Myers Squibb Co Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
DE10361794B3 (de) * 2003-12-31 2005-10-06 Schering Ag Optisch aktive heteroaromatische ß-Hydroxy-Ester und Verfahren zu deren Herstellung sowie deren Verwendung als Zwischenprodukte bei der Epothilon-Totalsynthese
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN100384419C (zh) * 2005-12-02 2008-04-30 菏泽睿鹰制药集团有限公司 一种埃坡霉素缓释植入组合物及应用
DE102007016046A1 (de) 2007-03-30 2008-10-23 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von Epothilonderivaten durch selektive katalytische Epoxidierung
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
WO2014202775A1 (en) 2013-06-21 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54115320A (en) * 1978-02-28 1979-09-07 Soda Aromatic Novel unsaturated keto acid and its manufacture
JP2653663B2 (ja) * 1988-02-15 1997-09-17 財団法人微生物化学研究会 １．３―ジヒドロキシ―８―デセン―５―オンを含む免疫賦活剤及び制癌剤
EP0469480A3 (en) * 1990-08-01 1993-03-10 Hoechst Aktiengesellschaft Process for stereoselective preparation of 5-substituted delta-lactones and their use
ZA981575B (en) * 1997-02-25 1998-09-08 Biotechnolog Forschung Gmbh Epothilones which are modified in the side chain
EP1005465B1 (de) * 1997-08-09 2007-07-25 Bayer Schering Pharma Aktiengesellschaft Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung

Also Published As

Publication number Publication date
JP4886578B2 (ja) 2012-02-29
TWI280962B (en) 2007-05-11
WO2000066589A1 (en) 2000-11-09
PL210762B1 (pl) 2012-02-29
BG106053A (en) 2002-05-31
CZ299653B6 (cs) 2008-10-08
CZ20013885A3 (cs) 2002-04-17
EA011502B1 (ru) 2009-04-28
EE200100568A (et) 2003-02-17
SK286858B6 (sk) 2009-06-05
MEP13908A (en) 2010-06-10
JP2002543203A (ja) 2002-12-17
NZ514989A (en) 2004-02-27
CA2651653A1 (en) 2000-11-09
CA2651653C (en) 2012-02-14
EP1173441A1 (en) 2002-01-23
AR023792A1 (es) 2002-09-04
DK1173441T3 (da) 2009-12-07
NO328149B1 (no) 2009-12-21
NO20015278D0 (no) 2001-10-29
BR0010190A (pt) 2002-01-08
KR100721488B1 (ko) 2007-05-23
CN1349534A (zh) 2002-05-15
ES2331506T3 (es) 2010-01-07
HK1046681A1 (en) 2003-01-24
BG65601B1 (bg) 2009-02-27
SI1173441T1 (sl) 2010-01-29
YU77601A (sh) 2005-07-19
PE20010116A1 (es) 2001-02-15
TWI294292B (en) 2008-03-11
HK1046681B (zh) 2008-08-29
JP4024003B2 (ja) 2007-12-19
ATE440847T1 (de) 2009-09-15
HUP0201010A2 (en) 2002-08-28
PL351491A1 (en) 2003-04-22
SK15512001A3 (sk) 2002-05-09
CA2371226A1 (en) 2000-11-09
HUP0201010A3 (en) 2005-02-28
EP1173441B1 (en) 2009-08-26
CN100368415C (zh) 2008-02-13
DE60042821D1 (de) 2009-10-08
EA200101025A1 (ru) 2002-06-27
HRP20010892A2 (en) 2008-06-30
IL145938A0 (en) 2002-07-25
KR20020005737A (ko) 2002-01-17
ZA200109859B (en) 2003-02-28
MXPA01011039A (es) 2003-06-30
PT1173441E (pt) 2009-11-06
TW200711679A (en) 2007-04-01
CA2371226C (en) 2011-11-29
EE05292B1 (et) 2010-04-15
RS51023B (sr) 2010-10-31
CY1109768T1 (el) 2014-09-10
JP2007224038A (ja) 2007-09-06

Similar Documents

Publication Publication Date Title
NO20015278D0 (no) 6-alkenyl-, 6-alkynyl- og 6-epoksy-epotilonderivater, fremgangsmåte for deres fremstilling og deres anvendelse ifarmasöytiske preparater
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
EE05109B1 (et) Sulfoonamiidi derivaadid, nende kasutamine meditsiinis ning meetod nende valmistamiseks
NO963506D0 (no) 4-Heterocyklyl-substituerte kinazolin-derivater, fremgangsmåte for fremstilling derav og deres anvendelse som anti-kreftmidler
NO924650D0 (no) Dialkoksy-pyridinyl-benzimidazolderivater, fremgangsmaate for deres fremstilling og deres farmasoeytiske anvendelse
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
NO20014270D0 (no) Pyridopyranoazepinderivater, deres fremstilling og terapeutisk anvendelse
IS6420A (is) Setnar Fenýl-píperazín afleiður, framleiðsla þeirra og notkun
DK1043307T3 (da) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
EE200100422A (et) Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
NO20016247D0 (no) Streptograminderivater, deres fremstilling og preparater inneholdende derivatene
NO20001905D0 (no) Forbindelser og deres anvendelse i farmasøytiske eller kosmetiske preparater
NO20022022D0 (no) N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20016404D0 (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20013878L (no) (1-fenacy-3-fenyl-3-piperidylety)piperidinderivater, fremgangsmåte for fremstilling derav og farmasöytiske preparaterinneholdende de samme
DK1086077T3 (da) Hidtil ukendte antiestrogener, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse
NO20025028D0 (no) 9-oksa-epotilonderivater, fremgangsmåte for fremstilling derav samt deres anvendelse i farmasöytiske preparater
NO20013141D0 (no) Arylalkanoylderivater, fremgangsmåte for fremstilling derav, deres anvendelse og farmasöytiske produkter inneholdende disse
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
NO20020777L (no) Farmasöytiske preparater inneholdende derivater og fremgangsmåte for fremstilling derav
DK1183241T3 (da) Spiroimidazolidinderivater, deres præparation, deres anvendelse og farmaceutiske præparationer omfattende disse
NO20001782D0 (no) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO20020404D0 (no) Streptograminderivater, deres produksjon og forbindelser derav
EE200200266A (et) 2-arüülkinoliini derivaadid, nende valmistamine ja kasutamine ravimites

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

MM1K Lapsed by not paying the annual fees